Megumi Iwamoto, Hiromitsu Asashima, Toshiki Sugita, Fumina Kawashima, Naoki Sugita, Akiyoshi Rai, Yuki Kuroda, Akira Kawashima, Daiki Tabuchi, Satoshi Akao, Ryota Sato, Taihei Nishiyama, Hirofumi Toko, Fumika Honda, Ayako Ohyama, Ayako Kitada, Saori Abe, Haruka Miki, Shinya Hagiwara, Yuya Kondo, Hiroto Tsuboi, Isao Matsumoto
IgG4-related disease (IgG4-RD) is a systemic condition in which IgG4+ plasma cell infiltration and fibrosis cause organ swelling and lead to diverse clinical manifestations. Although IgG4-RD typically responds to glucocorticoids (GCs), relapse during tapering occurs and an early GC-sparing approach might therefore be beneficial. Systemic lupus erythematosus (SLE) is a chronic inflammatory disease with multiple symptoms that is also treated with GCs as a first-line therapy. Recently, belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits B-cell activating factor, was approved, but reports of use for IgG4-RD are scarce...
January 3, 2024: Rheumatology International